The B- BBB rating is adequate, sitting in the middle tier and suggesting the company handles most complaints reasonably well
and L.P.-M
A recent Cornell University report found the share of US households reporting at least one GLP-1 user rose from around 11% in late 2023 to more than 16% by mid-2024
Cagrilintide covers amylin receptors 1 and 3
Competing interests PG has received occasional fees, either personally or institutionally, for the activities of speaking, scientific advising, or clinical research from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, Organon, Pfizer, and Sanofi